hiv-2 eho isolate has a divergent envelope gene and induces single cell killing by apoptosis.

NLM AIDSLINE HIV-2 EHO isolate has a divergent envelope gene and induces single cell killing by apoptosis. Rey-Cuille MA; Galabru J; Laurent-Crawford A; Krust B; Montagnier L;
September 30, 1994

Virology. 1994 Jul;202(1):471-6. Unique Identifier : AIDSLINE The human immunodeficiency virus type 2 (HIV-2)-related isolate, referred to as HIV-2 EHO, has been isolated from an Ivory Coast patient with acquired immunodeficiency syndrome (AIDS). Infection of CD4 expressing cells with this highly infectious virus mediates a cytopathic effect characterized by single-cell killing as a consequence of apoptosis. Nucleotide sequence analysis of the HIV-2 EHO genome revealed a significant degree of divergence of its envelope gene from that of other known HIV-2 strains. This divergence for the deduced amino acid sequence corresponding to the extracellular envelope glycoprotein was 26 to 30%. These unique genetic and biological properties suggest that the HIV-2 EHO isolate is a distinct prototype in the HIV-2 family. Acquired Immunodeficiency Syndrome/MICROBIOLOGY Amino Acid Sequence Apoptosis Cells, Cultured Genes, env Giant Cells/MICROBIOLOGY Human HIV Envelope Protein gp120/GENETICS HIV-2/CLASSIFICATION/GENETICS/PATHOGENICITY Molecular Sequence Data Sequence Homology, Amino Acid Support, Non-U.S. Gov't Variation (Genetics) JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases Adopted Russian orphan triumphs over challenges 26th Annual Minnesota AIDS Walk - Sunday, May 19, Minnehaha Park 'Gap' for HIV vaccine efforts after latest setback AIDS science at 30: 'Cure' now part of lexicon ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common 'Gap' for HIV vaccine efforts after latest setback AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine Health group didn't disclose HIV tests, apologizes NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents Danish researchers issue statement: "We are not on the brink of an HIV cure"
Information in this article was accurate in September 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.